The UK Competition and Markets Authority has revealed the reasoning behind its decision to fine Pfizer and Flynn Pharma for abuse of a dominant market position by charging “excessive and unfair” prices for the generic anti-epilepsy drug, phenytoin sodium capsules.
The CMA says the companies faced only “weak” competitive constraints in the form of other formulations of phenytoin sodium or...






